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A B S T R A C T
Background: Organizations in knowledge-intensive industries such as the field of PharmaNutrition benefit from a
critical consideration of intangible resources for innovation performance and competitive advantage. Effective
management of these resources, however, is complicated due to difficulties in their identification, appropriation,
application, and evaluation. As a consequence, knowledge-intensive organizations are at risk of suboptimal
exploitation of their most important value drivers.
Methods: The literature on organizational intangible resources was reviewed as part of an ongoing investigation
into effective management of intangible resources in the PharmaNutrition-specific context.
Results: Although high-level dimensions of intangible resources are recognized across industries, the identity and
relevance of various lower-level components are heterogenous and dependent on organization’s unique situa-
tional attributes. Despite the existence of historical, industry-sourced tick-the-box lists presented here, an ana-
lysis of industry-specific characteristics of intangible resources and mechanisms to appropriate their value is
warranted to enable practitioners to innovate effectively and efficiently.
Conclusions: This editorial aims to put the topics of intangible resources and their appropriability on the agenda,
and invites scholars and practitioners to contribute to the advancement of our understanding regarding these
topics through an online survey.
1. Introduction
For organizations in knowledge-intensive industries, intangible re-
sources are considered to be critical factors for organizational perfor-
mance, innovation, and value creation [1–3] Collectively referred to as
the organization’s intellectual capital (IC), these intangible resources
entail the non-physical, non-monetary means that are available to the
organization through its employees, organizational structures, and ex-
ternal relationships [4–7]. The resource-based view of the firm was the
first to put emphasis on the importance of these intangible resources,
arguing that they represent the main source of sustainable competitive
advantage [8,9]. According to the resource-based view, these ‘strategic
assets’ are the only resources that are truly valuable, rare, non-sub-
stitutable and imperfectly imitable [10].
Early research on the different components of IC has endorsed the
resource-based view of the firm in its notion that intangible resources
function as a primary source of competitive advantage and superior
performance [11–15]. Since, a growing body of literature stresses that
the roles and effects of IC and its different intangible components are
complex and heterogeneous, and therefore difficult to predict. Effective
management of intangible resources is further complicated due to their
hidden and elusive nature, which makes it difficult to identify, appro-
priate, apply, and evaluate intangible resources in organizational
practice. As a consequence, knowledge-intensive organizations, and
especially start- and scale-ups, are at risk of suboptimal exploitation of
their most important value drivers.
The industry segment between foods and pharmaceuticals (the
‘PharmaNutrition’ industry) represents an interesting case in terms of
the management of intangible resources. Here, successful realization of
innovative products—such as next-generation probiotics or persona-
lized medical nutrition—demands the contribution of knowledge, pro-
cesses, and technologies from both sides of this food-pharma interface,
and therefore effective relationships between people and organizations
from different industry backgrounds [16–18]. It follows that organiza-
tional performance and survival in this converging industry environ-
ment is particularly dependent on effective management of intangibles.
Despite this, the PharmaNutrition industry appears to have been fo-
cused primarily on tangible and registered intellectual property (IP)
resources [19,20]. At the same time, analyses of industry-specific in-
novation barriers and technological lifecycles have shown that novel
approaches to ensure competitive advantage—built upon an apprecia-
tion of intangible resources—are necessary to bring the field forward
[21–23]. As we have previously shown however, such approaches are
not clear-cut; innovation barriers result from a lack of understanding
and appreciation, and therefore a lack of proper consideration of in-
tangible resources relevant for stakeholders in the society and market
domains, which appear consistently underrepresented in academic in-
novation literature [24,25]. Technological advances and radical in-
novations in the sharing of information and resources between the
various stakeholders in this process can only partially accommodate for
this neglect [26].
It is no surprise that innovation performance is reduced without the
critical appreciation of intangible resources, as this critically informs
absorptive capacity—i.e., the ability to recognize, assimilate and apply
the value of external knowledge for improving the internal knowledge
base [27]—of organizations and industry value networks at large [28]
At the same time, we have seen that intangible resources can serve as
breakthroughs to the adoption of innovative technologies by market
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actors [29,30]. Indeed, industries that have adopted a strategic ap-
proach to intangible resources, like the organoids industry, have com-
bined technological disruptions with incredible market successes
[28,31]. Thus, a thorough understanding of how these intangible re-
sources relate to innovation processes and their success criteria in the
pharmanutrition industry is needed to contribute to enhanced innova-
tion performance, addressing unmet societal needs with improved ef-
ficiency [24,32–34].
2. Managing intangible resources: A closer look at appropriability
There’s general agreement on the high-level dimensions of IC being
human capital (e.g. employee knowledge and skills), structural capital
(e.g. organizational systems and practices), and relational capital (e.g.
industry partnerships). Research has however demonstrated that the
identity and relevance of the various lower-level IC components are not
equal for all types of organizations [10,35–39]. Rather, they are
heterogeneous and dependent on the organization’s unique situational
attributes [40,41]. It is therefore important to advance understanding
of the nature and dynamics of critical intangible resources in the
PharmaNutrition-specific context, to inform better management of IC
and thereby contribute to enhanced innovation performance.
Besides a picture (leading to a toolbox) of the industry-relevant in-
tangible resources and their relevance in organizational practice, it is
necessary that such understanding also covers the concept of appro-
priability—i.e., the ability of organizations to protect their intangible
resources against imitation so to that opportunities for both value creation
and value capture are improved, and investments in innovation activities
may be recouped. Appropriability of IC is complicated by many factors
that facilitate the flow of intangible resources in present-day industry
environments, including modern information and communication tech-
nology and high levels of employee mobility [42]. Yet, various appro-
priability mechanisms are at an organization’s disposal that may be
combined to shape an effective ‘appropriation regime’ [10,38,43–45].
Fig. 1. Appropriability mechanisms and intangible resources can be divided into different types.
Table 1
Industry sourcing of appropriability mechanisms and intangible resources have led to a historical tick-the-box list.
INDUSTRY-SOURCED AND NON-EXHAUSTIVE OVERVIEW
APPROPRIABILITY MECHANISMS & INTANGIBLE RESOURCES IN PHARMANUTRITION
Registered Contracted Embedded
AT COST / TAX • Confidential Disclosure Agreement
(CDA)
• Design & Product technology • Sales leads and knowledge
• Patents • Material Transfer Agreement (MTA) • Shapes and sizes • Office management / record
keeping
• Brand name • Invention Disclosure Form (IDF) • Plant and production design Asset management processes• Corporate name • Joint IP on improvements (license) • Technical data sheets • Employee education (in-house /
proprietary)
• Corporate logo • Trade secrets (vendors / suppliers /
employees)
• Process technology • Customer training (on- & off-site)
• Trademark • QA (e.g. ISO certification) • Formulation & Blending
technology
• Customer surveys
• Drawing & Model rights • QC & control standards (round-
robin test)
• Processing methods • Marketing training




• International research clearing
center
• Orphan Drug designation • Medical Foods (FDA; FSMP in EMA) • New and/or updated
technology
• Pricing policies / fee structures
• Other t.b.d. • Purchasing systems (soft- &
hardware)
• Secondary research • Customer lists and relations
• Employee benefits / retention • Internal QC standards • Consumer advertising
BY OWNER, AT NO / LOW COST • Employee education (outside) • Standard operating protocols
(SOPs)
• Promotional concepts and products
• Copyrights (Product; Labelling; Instructions for
use; Package; Advertisements)
• Business licenses (in- & out-) • Evaluation data / benchmarks • Worldwide public relations efforts
• Databases • Packaging technology and sourcing • Proprietary test results • Ad and graphics review• Trade secrets • Natural Step & FSSD Test facilities and research • Environmental / eco manufacturing• Social media • Other t.b.d. • Manuals / instructions / codes • Technical training / exchange
meetings
• Other t.b.d. • Regulatory knowledge /
experience
• Marketing strategy / umbrella
• Trade relationships • Other t.b.d.
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Patents, trademarks, copyrights, and other formal IP rights are well-
known examples of such mechanisms, as are non-disclosure agreements,
non-compete agreements, and other types of contracts. However, as in-
dicated in Fig. 1 and Table 1, a variety of other, informal mechanisms
exist that appear to have attracted less attention by scholars and practi-
tioners despite their potential efficacy [46]. Moreover, due to the great
heterogeneity of the IC concept, an overview of how existing appro-
priability mechanisms relate to the key components of IC in the Phar-
maNutrition-specific context remains absent. An analysis of the industry-
specific characteristics of IC appropriability is warranted as the absence of
such a consolidated overview makes it difficult for practitioners to
manage their IC, and thereby to innovate effectively and efficiently.
3. Next steps to advance understanding: an industry survey
This editorial aims to put the topics of IC, intangible resources, and
appropriability on the research agenda. We now invite scholars and
practitioners in the pharmanutrition industry to contribute to the ad-
vancement of understanding with regard to these topics, and have de-
veloped an online survey to facilitate this process. This survey can be
accessed through the following link, and will run from July to
September 2020: https://tinyurl.com/PhaNu-survey
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